Cambridge VC firm recruits former J.P. Morgan vice chairman
A top J.P. Morgan investment banker has jumped ship and will now carry the flag for healthcare.
A top J.P. Morgan investment banker has jumped ship and will now carry the flag for healthcare.
Flagship Ventures is now Flagship Pioneering, a rebrand that its CEO says better reflects its mission to discover and build first-of-its-kind science. It's a journey into the unknown — a journey that many U.S. innovators have taken before.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Nestlé first partnered with Pronutria last January, funding its nutraceutical approach to disease therapy, so its new stake in the company isn't surprising.
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
The company plans to enter the clinic by the close of 2016 with a red blood cell-based therapy that treats phenylketonuria.
Flagship Ventures has launched new company Evelo Therapeutics, which will be using an understanding of the microbiome to created targeted cancer treatment.
Cambridge firm Flagship Ventures just announced a series of corporate partnerships to flesh out early stage funding for its portfolio companies and scale its in-house accelerator, VentureLabs. It just teamed up with AstraZeneca, Nestlé Health Science and Bayer CropScience, using each of the companies’ market knowledge – and pipeline for product development and commercialization. The trio also have […]
Cambridge-based firm Flagship Ventures plans to launch as many as five new companies per year with its new, $537 million – its fifth, and the largest since its founding in 2000. With this new funding, the healthcare-focused VC firm will have some $1.4 billion under management. On top of therapeutics and the like, it’ll also form startups […]
How much more likely would a diabetic be to check his blood sugar regularly, or a nervous patient to fulfill her doctor’s request for blood work, if there were no “ouch” factor involved? Howard Weisman, the CEO of Seventh Sense Biosystems, said the painless blood draw system his company is developing could show us the […]
The company said it needed to raise the money to keep up with demand. Accuri launched its Accuri C6 Flow Cytometer in April 2008 and followed that launch three months later with a $13 million raise to expand its marketing and sales efforts of the product.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.